Know Cancer

forgot password

A Phase II Study of Alemtuzumab in Combination With CHOP as First-Line Treatment in Peripheral T-Cell Lymphoma

Phase 2
15 Years
65 Years
Not Enrolling
Peripheral T-Cell Lymphoma

Thank you

Trial Information

A Phase II Study of Alemtuzumab in Combination With CHOP as First-Line Treatment in Peripheral T-Cell Lymphoma

Peripheral T-cell lymphomas (PTCL) are more common in Asia than in Europe and United States
(17-40% vs. 5-10%). Most studies reported a poorer prognosis for PTCL compared to B-cell
non-Hodgkin's lymphomas (NHL).

CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) is currently regarded as
a standard chemotherapy regimen for patients with newly diagnosed NHL.

Alemtuzumab (Campath-1H) is a humanized monoclonal antibody that targets CD52, a cell
surface protein present at high density on most normal and malignant B and T
lymphocytes.Malignant T cells express particularly high numbers of CD52 cell surface markers
(approximately 500,000 molecules/lymphocytes),T-cell malignancies may thus be particularly
responsive to alemtuzumab.

As the response rate tend to be higher in patients newly diagnosed with PTCL, this study
evaluates the efficacy of alemtuzumab in combination with CHOP administered as up-front
therapy in patients newly diagnosed with PTCL in terms of response rate and overall

Inclusion Criteria:

- Patients must have a diagnosis of one of the following histologic types according to
the WHO classification:

- Angioimmunoblastic T-cell lymphoma

- Extranodal NK/T-cell lymphoma,nasal type

- Enteropathy-type T-cell lymphoma

- Hepatosplenic gamma-delta T-cell lymphoma

- Subcutaneous panniculitis-like T-cell lymphoma

- Anaplastic large-cell lymphoma,T/null cell,primary systemic type

- Peripheral T-cell lymphoma,not otherwise characterized

- Newly diagnosed,age 15-65 years.

- Complete work up for baseline evaluation and measurement (Appendix B)

- Patient's free written inform consent.

Exclusion Criteria:

- Patients with a known hypersensitivity to murine proteins or to any component of

- Patients who have received prior antilymphoma treatment with chemotherapy or

- Patients with poor performance status (PS;ECOG criteria of 3-4)(Appendix C).

- Serologic evidence of HCV and HCV RNA of chronic hepatitis.

- Serologic evidence of HBV and HBV RNA of chronic hepatitis.

- Patients with history of impaired cardiac status or myocardial infarction.

- Patients with serum creatinine >= 1.8 mg/dl,bilirubin >= 1.5 times upper limit of
normal range,SGOT or SGPT >= 3 times upper limit of normal range, unless due to tumor

- Patients with active uncontrolled infection,active non-malignant gastric or duodenal
ulcer, uncontrolled diabetes mellitus or other severe medical conditions which would
preclude aggressive cytotoxic chemotherapy.

- Active secondary malignancy.

- Pregnant or lactating women.

- Serious medical or psychiatric illness which prevent informed consent.

- Patients who are likely to lost to follow up (eg, unwilling or difficult to
return,cannot be contacted).

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the effectiveness of alemtuzumab given in combination with CHOP in terms of the rates of objective response rate (ORR:complete remission[CR] and

Principal Investigator

Surapol Issaragrisil, M.D.,Prof.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Siriraj Hospital


Thailand: Food and Drug Administration

Study ID:

TH 011002



Start Date:

September 2006

Completion Date:

August 2009

Related Keywords:

  • Peripheral T-cell Lymphoma
  • MabCampath + CHOP in PTCL
  • Lymphoma
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Peripheral